The REWIND trial for dulaglutide showed a 12% reduction in major cardiovascular events (heart attack, stroke, or cardiovascular death) over a median of 5.4 years
If it's working better for you now, I'd really appreciate it if you could update your review to reflect the changes
However, sometimes switching medications has benefits unrelated to weight loss
If youre ready to take a step toward personalized weight management, lets explore you options
The decrease in GPX4 further promotes SQSTM1 as an ARNTL autophagy vector, facilitating the occurrence of clock autophagy and inhibiting EGLN2 expression

Generally appropriate for: Adults with a BMI over 27 seeking medically-supervised weight loss People who have not achieved adequate results with diet and exercise alone Those looking for sustainable, long-term weight management support Adults without a history of thyroid or pancreatic conditions Generally not appropriate if: Pregnant or breastfeeding individuals People with a personal or family history of medullary thyroid carcinoma Those with multiple endocrine neoplasia syndrome type 2 (MEN 2) Patients with a history of pancreatitis without prior provider evaluation Common side effects: Nausea (most common, especially early in treatment, typically improves) Decreased appetite (expected and therapeutic) Mild diarrhea or constipation Occasional vomiting or stomach discomfort These typically subside as your body adjusts to the medication Individual results vary